Zoonotic infection define risk factor etiological agent mode of transmission

Reading File

Finding Sources

Searching the Web

zoonotic infections definition risk factors etiological agents modes of transmission

Finding Sources

Reading Web Page

zoonotic infection definition risk factors etiological agent mode of transmission

Reading File

Finding Sources

Reading File

I now have comprehensive textbook and reference data. Let me compile the full answer.

Zoonotic Infections

Definition

A zoonosis (pl. zoonoses) is an infection or disease naturally transmissible from vertebrate animals to humans (or from humans to animals). Zoonoses make up a significant proportion of all emerging infections and are caused by a complete range of pathogens - prions, viruses, bacteria, fungi, protozoa, and helminths. They are distinct from anthroponoses (diseases that only involve humans).

The core concept is zoonotic "spillover": barriers that normally prevent zoonotic agents from reaching humans are breached, allowing the pathogen to establish infection in a new host species.

Goldman-Cecil Medicine, p. 3297

Etiological Agents (by pathogen type)

Pathogen Type	Examples
Viruses	Rabies virus, SARS-CoV-2, MERS-CoV, Nipah virus, Hendra virus, West Nile virus, Eastern equine encephalitis virus, influenza A (avian/swine), Ebola, Monkeypox, Hantavirus
Bacteria	Yersinia pestis (plague), Borrelia burgdorferi (Lyme disease), Leptospira spp., Coxiella burnetii (Q fever), Brucella spp. (brucellosis), Bartonella henselae (cat-scratch disease), Francisella tularensis (tularemia), Pasteurella multocida, Capnocytophaga canimorsus, Spotted fever Rickettsia spp., Salmonella spp., Campylobacter spp.
Protozoa	Plasmodium knowlesi (zoonotic malaria), Babesia microti, Leishmania spp., Trypanosoma spp. (sleeping sickness, Chagas disease), Toxoplasma gondii
Helminths	Echinococcus spp. (hydatid disease), Toxocara spp.
Fungi	Ringworm (dermatophytes)
Prions	Variant Creutzfeldt-Jakob disease (vCJD) from BSE-infected cattle

Modes of Transmission

1. Direct Contact

Contact with infected animals, their body fluids, blood, tissues, or excretions. Risk is highest for veterinarians, farmers, abattoir workers, and animal handlers.

Examples: Leptospira (contact with rodent urine), Coxiella burnetii (inhalation of contaminated birth products/excretions from infected animals), ringworm

2. Animal Bites and Scratches

Dog bites: ~4.5 million/year in the US; ~900,000 result in infection. Agent: Capnocytophaga canimorsus, rabies
Cat bites/scratches: Pasteurella multocida, Bartonella henselae (cat-scratch disease)
Bat bites: Rabies

3. Arthropod Vector Bites (Vector-borne)

Ticks: Borrelia burgdorferi (Lyme disease) - the single largest category in the US (90% of vector-borne zoonoses); Rickettsia spp. (spotted fever); tick-borne relapsing fever
Mosquitoes: West Nile virus, Plasmodium knowlesi, Rift Valley fever
Flies (tsetse): Trypanosoma brucei spp. (African sleeping sickness)
Sandflies: Leishmania spp. (700,000-1 million new cases/year)
Fleas/lice: Typhus (Rickettsia)
Trombiculid mite (chigger): Scrub typhus (Orientia tsutsugamushi)

4. Foodborne / Waterborne

Consumption of contaminated meat, dairy, or water
Examples: Salmonella spp., Campylobacter spp., Shiga toxin-producing E. coli (STEC), hepatitis E virus, Brucella spp. (unpasteurized milk), Listeria spp., norovirus

5. Airborne / Inhalation

Inhalation of aerosolized animal excretions, dusts
Examples: Coxiella burnetii (Q fever), Hantavirus (rodent droppings), Histoplasma (bird/bat guano)

Risk Factors

Host (Human) Factors

Occupation: Veterinarians, farmers, abattoir/slaughterhouse workers, hunters, animal handlers, laboratory workers - highest occupational risk
Recreation: Wildlife observation, camping, hiking, hunting (>90 million US residents exposed)
Pet ownership: ~60% of Americans own pets (dogs, cats, reptiles, exotic animals)
Immunocompromised status: HIV/AIDS, organ transplant, chemotherapy - increased susceptibility and severity
Lack of hygiene awareness: Inadequate handwashing, poor sanitation, consuming undercooked food
Genetic predisposition to specific pathogens

Environmental / Ecological Factors

Tropical forest regions: Highest biodiversity and spillover risk
Increased mammal biodiversity: More reservoir hosts available
Land use changes: Agricultural encroachment into forests, urban development, residential expansion - the strongest predictor of emergence risk
Illegal wildlife trade: Direct exposure to novel pathogens
Climate change: Rising temperatures, floods, and increased vector (mosquito, tick, mite) populations expected to increase zoonoses over the next 50 years
Loss of biodiversity and ecosystem collapse

Pathogen / Exposure Factors

Wildlife contact: Most emerging zoonoses are acquired from wildlife
Exotic/wild animal markets: High-risk settings for novel pathogen exposure (e.g., SARS, COVID-19 origins)
Globalization of livestock and meat markets: Wider geographic spread of pathogens
Antimicrobial resistance: Overuse of antibiotics in livestock promotes resistant zoonotic strains

Classification Summary

Category	Mode	Example Disease
Direct zoonosis	No intermediate host needed	Rabies, ringworm
Cyclo-zoonosis	Requires >1 vertebrate host	Echinococcosis
Meta-zoonosis	Requires invertebrate vector	Lyme disease, leishmaniasis
Sapro-zoonosis	Environmental reservoir	Anthrax, histoplasmosis

Sources:

Goldman-Cecil Medicine, International Edition, Chapter 303 - Zoonoses, pp. 3297-3299
Zoonotic Diseases: Etiology, Impact, and Control - PMC7563794
WHO Zoonoses Fact Sheet

Drug used in glucoma

Finding Sources

Searching the Web

drugs used in glaucoma pharmacology mechanism of action

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive textbook data from Katzung's Pharmacology and Wills Eye Manual. Here is the full, detailed answer:

Drugs Used in Glaucoma

Pathophysiology Basis

Glaucoma is a major cause of blindness driven by raised intraocular pressure (IOP). IOP is maintained by a balance between aqueous humor production (by the ciliary epithelium) and its drainage (mainly through the trabecular meshwork). Drugs work by either reducing aqueous secretion or increasing aqueous outflow - or both.

Two main types matter clinically:

Open-angle glaucoma - chronic, managed largely with pharmacotherapy
Closed/narrow-angle glaucoma - acute, painful emergency requiring urgent IOP reduction plus surgery (iridectomy)

Drug Classes

1. Prostaglandin Analogs (First-line)

Drug	Route	Dosing
Latanoprost	Topical	Once daily (evening)
Bimatoprost	Topical	Once daily
Travoprost	Topical	Once daily
Tafluprost	Topical	Once daily
Unoprostone	Topical	Twice daily

Mechanism: Increase aqueous outflow via the uveoscleral (non-trabecular) pathway by activating FP prostaglandin receptors in the ciliary muscle.

Advantages: Once-daily dosing, highly effective, minimal systemic side effects. Currently the drugs of choice to initiate treatment.

Side effects: Increased iris pigmentation (brown discoloration), periorbital skin darkening, eyelash lengthening (hypertrichosis), conjunctival hyperemia.

2. Beta-Adrenergic Blockers

Drug	Selectivity	Route
Timolol	Non-selective (β1+β2)	Topical
Betaxolol	β1-selective	Topical
Carteolol	Non-selective	Topical
Levobunolol	Non-selective	Topical
Metipranolol	Non-selective	Topical

Mechanism: Block β receptors on the ciliary epithelium → decrease aqueous humor secretion.

Advantages: Still widely used, especially in combination therapy and in patients who cannot afford prostaglandins.

Contraindications: Asthma, COPD, bradycardia, heart block, heart failure (systemic absorption can occur even from eye drops).

3. Alpha-2 Adrenergic Agonists

Drug	Notes
Brimonidine (0.1%, 0.15%, 0.2%)	More selective, fewer systemic effects
Apraclonidine	Higher incidence of adverse effects

Mechanism: Stimulate α2 receptors → decrease aqueous secretion + increase uveoscleral outflow.

Uses: Second-line; also used to prevent IOP spikes after laser procedures.

Side effects: Ocular allergy (up to 30% with apraclonidine), drowsiness, dry mouth, lid retraction.

4. Carbonic Anhydrase Inhibitors (CAIs)

Drug	Route
Dorzolamide 2%	Topical (eye drops)
Brinzolamide 1%	Topical (eye drops)
Acetazolamide	Oral / IV (systemic)
Methazolamide	Oral

Mechanism: Inhibit carbonic anhydrase in the ciliary epithelium → decrease bicarbonate and aqueous humor secretion.

Key clinical point: Topical forms (dorzolamide, brinzolamide) are used for chronic open-angle glaucoma. Acetazolamide IV (250-500 mg) is given urgently in acute angle-closure attacks.

Contraindications: Sulfonamide allergy, sickle cell disease (systemic CAIs). Systemic forms cause metabolic acidosis, renal stones, hypokalemia, and paresthesias.

5. Cholinomimetics (Miotics)

Drug	Notes
Pilocarpine (1-4%)	Prototype; used topically
Carbachol	Topical

Mechanism: Muscarinic agonists → contract the ciliary muscle and sphincter pupillae → open trabecular meshwork → increase aqueous outflow.

Uses: Acute angle-closure glaucoma (pilocarpine 1% is given as part of the emergency regimen); also chronic open-angle glaucoma.

Side effects: Miosis (poor night vision), brow ache, increased lacrimation, increased salivation. Higher incidence of topical adverse effects - less preferred now.

6. Rho Kinase (ROCK) Inhibitors

Drug	Notes
Netarsudil	Topical, once daily
Ripasudil	Used in Japan

Mechanism: Inhibit Rho kinase → relax trabecular meshwork → increase conventional (trabecular) outflow + reduce episcleral venous pressure.

Notes: Relatively newer agents; less long-term data. May cause conjunctival hyperemia and cornea verticillata.

7. Osmotic Agents (Acute/Emergency)

Drug	Route	Use
Mannitol (20%)	IV (1-2 g/kg over 45 min)	Acute angle-closure emergency
Glycerin	Oral	Acute IOP lowering

Mechanism: Create an osmotic gradient → draw fluid from the vitreous → rapidly reduce IOP.

Contraindicated in: Congestive heart failure, renal disease, intracranial bleeding (mannitol).

Summary Table

Class	Drugs	Mechanism	Effect on Aqueous
Prostaglandin analogs	Latanoprost, bimatoprost, travoprost	↑ Uveoscleral outflow	↑ outflow
Beta-blockers	Timolol, betaxolol	↓ Ciliary body secretion	↓ production
Alpha-2 agonists	Brimonidine, apraclonidine	↓ Secretion + ↑ outflow	Both
CAIs	Dorzolamide, acetazolamide	↓ Bicarbonate/secretion	↓ production
Miotics	Pilocarpine, carbachol	↑ Trabecular outflow	↑ outflow
ROCK inhibitors	Netarsudil	↑ Trabecular outflow	↑ outflow
Osmotic agents	Mannitol, glycerin	Osmotic fluid draw	Acute reduction

Treatment Approach

Chronic open-angle glaucoma: Start with a prostaglandin analog (latanoprost, once daily). Add a beta-blocker or other agent if IOP target not reached.
Acute angle-closure attack (emergency):
1. Topical: beta-blocker + alpha-2 agonist + pilocarpine 1% + CAI drops (given in 3 rounds, 15 min apart)
2. Systemic: acetazolamide 250-500 mg IV
3. If refractory: IV mannitol 1-2 g/kg
4. Definitive: laser peripheral iridectomy
Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 256
The Wills Eye Manual, p. 571

Drugs used in migraine

Finding Sources

Searching the Web

drugs used in migraine abortive prophylactic pharmacology 2024

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive textbook data from Goodman & Gilman's and Kaplan & Sadock's. Here is the complete answer:

Drugs Used in Migraine

Pathophysiology Basis

Migraine affects 10-20% of the population. The pathogenesis involves both neural and vascular elements, with serotonin (5-HT) as a key mediator. During an attack, plasma/platelet 5-HT levels fall while urinary 5-HT metabolites rise. CGRP (calcitonin gene-related peptide) is also a major mediator of neurogenic inflammation and vasodilation in migraine. Drugs either target the acute attack or prevent future attacks.

A. ACUTE (ABORTIVE) TREATMENT

Goal: Stop the attack as quickly as possible - begin treatment at onset.

1. Triptans - 5-HT 1B/1D Receptor Agonists (Drug of Choice for Moderate-Severe Migraine)

Drug	Dose (mg)	Route
Sumatriptan	25, 50, 100	Oral, SC, intranasal
Zolmitriptan	2.5, 5	Oral, intranasal
Rizatriptan	5, 10	Oral
Naratriptan	2.5	Oral
Eletriptan	20, 40, 80	Oral
Almotriptan	12.5	Oral
Frovatriptan	2.5	Oral (longest t½)

Mechanism: Selective agonists at 5-HT1B (vasoconstriction of dilated intracranial vessels) and 5-HT1D (inhibit release of pro-inflammatory neuropeptides from perivascular trigeminal nerve terminals) receptors. Also reduce nausea and vomiting of migraine.

Key points:

All triptans have roughly equivalent efficacy
Start as soon as possible after attack onset
Oral formulations are most convenient; injectable/nasal sprays used when nausea/vomiting prevents oral intake
Not for prophylaxis (exception: frovatriptan for menstrual migraine prevention)
Sumatriptan + naproxen is an approved fixed-dose combination

Contraindications: Ischemic heart disease, uncontrolled hypertension, hemiplegic migraine, stroke/TIA, pregnancy (relative). Avoid combining with ergotamines or MAOIs.

2. Ergot Alkaloids (Older; Now Less Used)

Drug	Route
Dihydroergotamine (DHE)	Intranasal, IM, IV
Ergotamine + caffeine	Oral/sublingual

Mechanism: Partial agonists/antagonists at serotonergic, dopaminergic, and adrenergic receptors - cause vasoconstriction.

Note: The European Medicines Agency has recommended ergot derivatives no longer be used for migraine due to risk of coronary and endocardial fibrosis. Largely replaced by triptans. DHE is still used for status migrainosus in hospital settings.

Contraindications: Coronary artery disease, peripheral vascular disease, pregnancy, hypertension.

3. NSAIDs and Analgesics (Mild-Moderate Migraine)

Drug	Dose
Aspirin	325-1000 mg
Naproxen sodium	500-550 mg
Diclofenac potassium	50-150 mg
Ibuprofen	400-800 mg
Acetaminophen/Paracetamol	1000 mg

Mechanism: Inhibit prostaglandin synthesis (COX inhibition), reducing neurogenic inflammation.

Use: First-line for mild-moderate attacks; OTC availability makes them widely used.

4. Antiemetics (Adjuncts)

Drug	Notes
Metoclopramide	Also improves GI motility - enhances absorption of oral analgesics
Prochlorperazine	Useful IV in emergency settings
Domperidone	Reduces nausea, aids drug absorption
Ondansetron	5-HT3 antagonist

Role: Treat nausea/vomiting and improve absorption of oral migraine drugs. Given before or alongside analgesics/triptans.

5. Newer Acute Agents (CGRP Pathway)

Gepants - CGRP Receptor Antagonists (Small Molecule)

Drug	Notes
Rimegepant	Oral; can be used for both acute AND prevention
Ubrogepant	Oral; acute treatment
Atogepant	Oral; primarily for prevention

Mechanism: Block CGRP receptor → reduce neurogenic vasodilation and inflammation. No vasoconstriction - safe in cardiovascular disease where triptans are contraindicated.

Lasmiditan - 5-HT1F Agonist ("Ditan")

Selective 5-HT1F agonist; no vasoconstrictive properties
Safe in cardiovascular disease
Side effects: dizziness, somnolence - cannot drive for 8 hours after use

6. Opioids (Rescue Only)

Butorphanol nasal spray, codeine combinations
Generally avoided due to risk of medication overuse headache (MOH) and dependence. Last-resort rescue therapy only.

B. PROPHYLACTIC (PREVENTIVE) TREATMENT

Indicated when: attacks ≥4/month, severe/prolonged attacks, frequent rescue medication use, or contraindication to abortive drugs.

Goal: Reduce attack frequency by ≥50%.

Established Efficacy

Class	Drug	Dose
Beta-blockers	Propranolol	80-240 mg/day
	Metoprolol	100-200 mg/day
	Timolol	20-60 mg/day
	Atenolol, Nadolol	(probable efficacy)
Antiseizure drugs	Topiramate	50-200 mg/day
	Valproate/Divalproex sodium	500-1500 mg/day
CGRP monoclonal antibodies	Erenumab (anti-CGRP receptor)	70-140 mg SC monthly
	Fremanezumab (anti-CGRP)	225 mg SC monthly or 675 mg quarterly
	Galcanezumab (anti-CGRP)	120 mg SC monthly
	Eptinezumab (anti-CGRP)	100-300 mg IV quarterly
Neurotoxin	OnabotulinumtoxinA (Botox)	155 units IM every 12 weeks (chronic migraine)

Probable Efficacy

Class	Drug
Antidepressants	Amitriptyline (TCA) - most evidence
	Venlafaxine (SNRI)
	Nortriptyline, Desipramine (TCAs)
Calcium channel blockers	Flunarizine (not available in US), Verapamil
Triptans	Frovatriptan (menstrual migraine prevention)

Note: SSRIs (fluoxetine, sertraline) do not have demonstrated efficacy in migraine prevention and may even worsen headaches in some patients.

C. Special Populations

Situation	Preferred Approach
Children	Topiramate, flunarizine; cyproheptadine <12 years
Pregnancy	Acetaminophen (safest); avoid triptans, valproate, ergotamines
Cardiovascular disease	Avoid triptans/ergotamines; use gepants or lasmiditan
Comorbid depression/anxiety	Amitriptyline, venlafaxine (address both)
Comorbid epilepsy	Valproate, topiramate
Comorbid hypertension	Beta-blockers, CCBs
Menstrual migraine	Frovatriptan (perimenstrual use)

Summary: Treatment Algorithm

Mild-Moderate attack → NSAIDs / Acetaminophen ± Antiemetic
Moderate-Severe attack → Triptan (first-line) or Triptan + NSAID combination
Cardiovascular risk / Triptan contraindicated → Gepant or Lasmiditan
Refractory / Status migrainosus → IV DHE, IV prochlorperazine, IV dexamethasone

≥4 attacks/month → Start Prophylaxis:
  First-line: Propranolol OR Topiramate OR Valproate
  Add: CGRP monoclonal antibody if ≥2 preventives fail
  Chronic migraine: OnabotulinumtoxinA

Sources:

Goodman & Gilman's The Pharmacological Basis of Therapeutics - 5-HT Receptor Agonists, Triptans (pp. 312-313)
Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Migraine Treatment Tables 2.11-5 and 2.11-6 (pp. 1990-1993)
BMJ 2024 comparative analysis of acute migraine drug interventions

This is a shared conversation. Sign in to Orris to start your own chat.